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Abstract. As biomedical sciences discover new layers of complexity in the mechanisms of life and 
disease, mathematical models trying to catch up with these developments become mathematically 
intractable. As a result, in the grand scheme of things, mathematical models have so far played an 
auxiliary role in biomedical sciences. We propose a new methodology allowing mathematical 
modeling to give, in certain cases, definitive answers to systemic biomedical questions that elude 
empirical resolution. Our methodology is based on two ideas: (1) employing mathematical models 
that are firmly rooted in established biomedical knowledge yet so general that they can account for 
any, or at least many, biological mechanisms, both known and unknown; (2) finding model 
parameters whose likelihood-maximizing values are independent of observations (existence of such 
parameters implies that the model must not meet regularity conditions required for the consistency 
of maximum likelihood estimator). These universal parameter values may reveal general patterns 
(that we call natural laws) in biomedical processes. We illustrate this approach with the discovery 
of a clinically important natural law governing cancer metastasis. Specifically, we found that under 
minimal, and fairly realistic, mathematical and biomedical assumptions the likelihood-maximizing 
scenario of metastatic cancer progression in an individual patient is invariably the same: Complete 
suppression of metastatic growth before primary tumor resection followed by an abrupt growth 
acceleration after surgery. This scenario is widely observed in clinical practice and supported by a 
wealth of experimental studies on animals and clinical case reports published over the last 110 years. 
The above most likely scenario does not preclude other possibilities e.g. metastases may start 
aggressive growth before primary tumor resection or remain dormant after surgery. 
Keywords: Cancer; metastasis; method of maximum likelihood; Poisson process.   
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1. Introduction: A New Methodology of Mathematical Modeling  
Physics has universal laws and by the grace of Nature they have precise mathematical form [1]. In 
molecular biology, various microscopic processes that are essentially physical or chemical, such as 
the action of molecular motors or kinetics of biochemical reactions, can also be described by fairly 
precise mathematical models. By contrast, in the systems biology of cells, organs and tissues as well 
as in medicine, no universal quantitative laws have ever been discovered. In their stead, biomedical 
sciences deal with qualitative or quantitative statements about biological objects or processes that 
are based on measurements, observations, theoretical arguments, rejection of alternatives, 
experience or intuition and are believed to be true for most biological organisms or patients of certain 
kind. We will call such statements, perhaps for lack of better term, natural laws. As one example, 
consider a statement, often made by medical doctors, that systematic consumption of certain foods, 
e.g. read meat products, increases the risk of a specific cancer. Two related factors make verification 
of this statement difficult. First, biological mechanisms behind this putative cause and effect 
relationship remain largely unknown (although hypotheses abound). Second, cancer risk-specific 
effects of diet are most likely individual, so that the above statement may be true for some people 
and false for others. Typically, statements like this are approached empirically based on the 
comparison of the number of people who have developed cancer among those with and without a 
particular diet habit or by comparing pre-diagnosis diets of cancer patients to those in the general 
population. Such comparisons, however, are methodologically problematic because cancer risk is 
influenced by many other factors correlated with diet such as genetic make-up, family history of 
cancer, age, BMI, amount of exercise, exposure to environmental or occupational hazards, and many 
others. The question we take up in this article is: Can natural laws in biomedical sciences be 
formulated in precise mathematical terms and discovered or confirmed unequivocally through 
mathematical modeling and statistical analysis?   
Mathematical modeling of biomedical systems, such as individual cells, multicellular organisms, 
patients or their populations, faces two principal challenges. The first is enormous complexity of 
biomedical processes. As biology and medicine uncover layer after layer of molecular mechanisms 
of life and disease, mechanistic mathematical models attempting to catch up with these 
developments gradually lose their mathematical tractability and eventually computational 
feasibility. The second challenge is great variability and heterogeneity of biological systems. This 
typically requires mathematical models to have stochastic components and include parameters 
accounting for individual variation.  
We propose here an alternative methodology of mathematical modeling in biomedical sciences. The 
new methodology is based on two ideas. The first is to build mathematical models that, on the one 
hand, are firmly grounded in the well-established biomedical knowledge but, one the other hand, 
eschew mechanistic details and are general enough to account for any, or at least many, mechanisms, 
both known and unknown. Simplicity and generality of such models, representing two of the 
mathematics’ most notable hallmarks and sources of strength, offer a greater chance to enable closed 
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form solutions and rigorous theoretical analysis than complex and highly specific mechanistic 
models.  
Mathematical models in biology and medicine depend on numerical and functional parameters, and 
the former can be estimated from observations. One of the most appealing ways to do so is to select 
parameter values that maximize the model-based probability of observations or, in the case of 
continuous observables, their joint probability density function (pdf). This time-tested method of 
parameter estimation, known as the Principle of Maximum Likelihood, goes back to Gauss, 
Lagrange, Euler, Daniel Bernoulli and Laplace [2].  
In general, the likelihood-maximizing values of parameters depend on observations. However, it 
may happen that some of them are universal, that is, the same for all admissible data sets. These 
universal parameter values are therefore a property of the model rather than a function of 
observations. Thus, if the model is general enough and depends only on a minimal set of reasonable 
assumptions, then one can hope to have thus discovered a general pattern in biomedical phenomena, 
i.e. a natural law. This likelihood-maximizing state of the biomedical system or pathway of the 
process does not exclude other possibilities; however, they are less likely to occur. This is the second 
idea underlying our new approach to mathematical modeling of biomedical phenomena.  To the best 
of our knowledge, the new methodology has never been employed in the past.  
Before we proceed, one statistical remark is in order. If data is generated by the model with a fixed 
set of parameters then one would expect the maximum likelihood estimators (MLEs) of numerical 
parameters based on this data to converge, as the sample size increases indefinitely, to the parameter 
values used to generate the data, which would prevent the existence of universal MLEs. However, 
this convergence property, called consistency of the MLE, is only true if the model satisfies certain 
regularity conditions, see e.g. [3, p. 202]. Therefore, allow data-independent MLEs, the model must 
not meet the regularity conditions.  
As an illustration of the new methodology, we apply it to cancer metastasis and obtain a definitive 
answer to a question of great clinical importance. Specifically, application of the Principle of 
Maximum Likelihood to an extremely general individual-patient model of cancer progression, see 
Section 3, has led us to a surprising discovery that the most likely scenario under the model is 
invariably the same: Complete suppression of the growth of metastases while primary tumor is in 
place followed by an abrupt acceleration of their growth following primary tumor resection, see [4] 
for more details. Importantly, this phenomenon was discovered in animals models more than a 
century ago [5-7], later confirmed in many other experimental studies on animals, and supported by 
countless clinical observations, see comprehensive reviews [8-12]. This finding also represents a 
common knowledge among veterinarians.  
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2. Primary Tumor and Metastases: A Brief Overview 
Over the last few decades, cancer has become a global pandemic. As one example, if the current 
trend in cancer incidence and mortality continues unabated more than a quarter of the world 
population and about 39% of people in the US (40% of men and 38% of women) will develop cancer 
over their lifetime and about half of them will die of cancer. The most clinically significant aspect 
of solid cancers is metastasis, which accounts for about 90% of all cancer-related deaths. In the grand 
scheme of things, mathematics and statistics have played so far an auxiliary role in cancer biology 
and oncology. As we will show below, they can give definitive answers to clinically important 
questions whose empirical resolution by biomedical sciences has been heretofore elusive.   
As every practicing oncologist knows, cancer patients seldom present with clinically manifest 
metastases. For example, even for renal cell carcinoma, an insidious kidney cancer that frequently 
progresses asymptomatically until advanced stages of the disease, 25-35% represents a historical 
maximum for the fraction of patients having clinical metastases at diagnosis (nowadays, due to 
widespread diagnostic imaging, this fraction is about 10-15%). Yet in a large fraction of cancer 
patients, metastases surface within weeks, months or years after surgical removal of the primary 
tumor. Is this just a coincidence or is there a cause and effect relationship between (a) the presence 
of the primary tumor and absence of clinical metastases; and (b) primary tumor resection and 
surfacing of metastases? Although numerous experiments on animals accumulated over more than 
110 years provide ample empirical evidence supporting the suppressing effect of the primary tumor 
and accelerating effect of its resection on metastasis, direct confirmation of this striking phenomenon 
and understanding of its causes in humans have evaded biomedical scientists so far, for three reasons. 
Firstly, subclinical micrometastases and critical microevents that trigger their origination and 
progression to detectable secondary tumors are largely unobservable. Secondly, such randomly 
occurring formative microevents are separated by months, years or even decades from their clinical 
manifestations. Finally, experimental verification of the above tentative natural law is restricted by 
ethical considerations. This makes the use of mathematical models indispensable for establishing 
qualitative and quantitative relationships between primary tumor and metastases.  
Over a few recent decades, cancer biology and oncology underwent a revolutionary transformation 
brought about by the discoveries of (1) mutational origins of cancer and genomic instability of cancer 
cells; (2) their metabolic plasticity; (3) aberrant regulation of cell cycle, proliferation and apoptosis 
in cancer cells; (4) the pivotal role of angiogenesis in tumor progression; (5) the significance of 
primary and secondary tumor dormancy; (6) complex interactions of cancer cells with the immune 
and endocrine systems; (7) a critical role of tumor microenvironment; (8) an important role of 
inflammation in cancer origination and progression; (9) identification of stem-like cancer cells; and 
(10) the importance of selection processes that bring about heterogeneity of cancer cell populations 
and frequently lead to failure of cancer treatment. Although they have all considerably changed the 
landscape of cancer research, they have not, unfortunately, brought about a revolution in cancer 
treatment, for a simple reason that many other important aspects of cancer still remain unknown. 
That is why when answering systemic questions about cancer like the one posed above one cannot 
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rely on mathematical models based on specific biological mechanisms – many of them have not yet 
been discovered! This, combined with insurmountable complexity of any mathematical model 
accounting for all the known mechanisms of cancer origination and progression, calls for a different 
approach; the one outlined in the Introduction serves precisely this purpose.   
The study of the interaction between various tumors within the same host has a long history starting 
with a pioneering work of 1906 by Paul Ehrlich [5] who discovered experimentally that tumor-
bearing animals frequently reject second tumors with which they were inoculated or suppress their 
growth. This and many other later studies have proved beyond reasonable doubt that large tumors 
may inhibit the growth of smaller ones, see comprehensive reviews [8, 11]. In particular, it was 
observed in animal experiments that primary tumor suppresses the growth of metastases [6-8, 11]. 
It comes as no surprise, then, that primary tumor resection is followed in many cases by rapid 
outgrowth of metastases. This effect was first reported in [6, 7] and later confirmed in many 
experimental studies and supported by numerous clinical case reports, as reviewed in [8-12].  
Additionally and importantly, any surgical intervention has metastasis-promoting effects of its own 
due to a variety of reasons including (1) increased local and systemic production of growth and 
angiogenesis factors required for wound healing; (2) transient inflammation that acts as universal 
cancer promoter; and (3) temporary immunosuppression that may cause metastases to escape 
immune surveillance.  
Solid primary tumors originate from a single malignant clonogenic cell. Unlike normal cells of the 
same tissue origin, cancer cells can evade internal, local and systemic signals that regulate cell cycle 
and apoptosis. Tumor growth is enabled by supply of nutrients, oxygen and growth factors initially 
delivered through diffusion. However, according to a fundamental discovery made by Judah 
Folkman in the 1970s [13], under such conditions a tumor can only reach a microscopic diameter of 
about 1-2 mm. To enable its further growth, the tumor has to induce angiogenesis, i.e. grow a 
capillary network that will provide a more efficient supply of essential chemicals. If the effects of 
angiogenesis inhibitors are stronger than those of angiogenesis promoters then the tumor will be in 
a state of dormancy characterized by a dynamic equilibrium between cell proliferation, death and 
quiescence. By contrast, if due to internal or external factors the balance shifts in favor of 
angiogenesis the tumor will vascularize and start an aggressive growth. This event, viewed below as 
instantaneous for the purpose of mathematical modeling, will be called primary tumor inception. 
A primary tumor may start shedding bloodborne metastases as soon as it becomes vascularized, i.e. 
following inception. Because the minimum diameter for clinical detection of tumors is about 5 mm, 
the aforementioned Folkman’s limit for the diameters of avascular tumors suggests that at the time 
of inception a primary or secondary tumor may still be undetectable.  
Metastasis is a complex multi-stage process [14]. A metastasis-generating cell has to separate itself 
from the primary tumor, degrade extracellular matrix, migrate to a blood vessel, intravasate, survive 
through the period of free circulation, extravasate, and invade a host site. A solitary metastatic cell 
lodged in a secondary site may remain dormant for months, years or even decades [15].  Under 
favorable conditions, it may start to grow, induce angiogenesis and eventually enter the clinical 
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stage. Thus, metastasis is a highly inefficient and selective process in that only a tiny fraction of 
cancer cells shed off the primary tumor give rise to clinically detectable secondary tumors. Just as 
for primary tumor, the start of active growth of a vascular metastasis will be termed inception.  
3. An Individual-Patient Mathematical Model of Metastatic Cancer 
An extremely general mathematical model described below focuses on well-established clinically 
important processes associated with metastasis while avoiding explicit description of their causes 
and mechanisms. For previously proposed particular cases of the model as well as its extensions and 
parametric versions, see [4, 16-21]. The model combines a deterministic law of growth of metastases 
in a given secondary site (typically lungs, liver, bones, brain or soft tissues) with a stochastic 
description of the processes that clearly depend on chance [22], such as shedding of metastases off 
the primary tumor, their survival, and dormancy in the given site. The “trick” here is that the rate of 
metastasis shedding and the distribution of metastasis latency times are essentially arbitrary.  
Primary tumor inception and observables. Let T be the unobservable age of primary tumor 
inception. Its significance is that it represents the earliest time when primary tumor may start 
shedding metastases. Denote by V the age at primary tumor resection and by W a later age at which 
several metastases were detected and measured in a given secondary site. Thus, 0 < T < V < W, see 
Fig. 1. Let m be the smallest measurable tumor size (i.e. the number of cells) in the site in question. 
Denote by X1, X2,..., Xn, where m < X1 ≤ X2 ≤ ... ≤ Xn, the sizes of the detected metastases. Such 
data can be obtained through laborious reading of CT/PET images, as exemplified in [16-21].  
 
 
        
 
 
    
      
 
 
Fig. 1. Timeline of the natural history of metastatic cancer and its treatment in an individual patient. All times 
are represented as ages counted from the birth of the patient. T+U is the age at inception of a particular 
metastasis. Note that the inception may occur either before or after surgery. Numbers with arrows above the 
timeline represent sizes of the metastasis at the indicated time points.  
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Metastasis generation. It is assumed that metastasis shedding off the primary tumor is governed by 
a Poisson process with rate r(t), where time t is counted from the age T. Recall that this means, by 
definition, that the numbers of metastases shed over non-overlapping time intervals are 
stochastically independent and that the number of metastases shed over any interval [s, t] is Poisson 
distributed with the expected value   , see e.g. [23, pp. 270-273]. We assume that function 
r is continuous and positive on [0, V-T) and that r(t) = 0 for t > V-T. Implicit in the latter condition 
are the assumptions that the resected primary tumor is non-recurrent and that secondary 
metastasizing (that is, formation of “metastasis of metastasis”) to a given site, both from other sites 
and from within, is negligible, which is commonly believed to be the case [24]. 
Progression of metastases. Metastases shed by the primary tumor are assumed to survive and give 
rise to clinically detectable secondary tumors in a given site independently of each other with the 
same probability q > 0; we will call such metastases viable. Therefore, see e.g. [25, pp. 257-259], 
inception of viable metastases in the site of interest is governed by the Poisson process with rate µ(t) 
= qr(t). Furthermore, each viable metastasis is assumed to spend some random time between 
detachment from the primary tumor and inception in the secondary site, termed metastasis latency 
time. This time includes dormancy of a metastasis as a solitary cancer cell and as an avascular 
micrometastasis lodged in the site of interest. Latency times of viable metastases bound for a given 
site are thought of as independent and identically distributed (iid) random variables with some 
continuous pdf f and the corresponding cumulative distribution function F. Then, the resulting 
delayed Poisson process is again a Poisson process with rate ∫ −
t
dsstfs
0
)()(µ , see e.g. [26]. Finally, 
we assume for simplicity that the growth of all vascular metastases in the site in question starts from 
the same initial size, N0, at inception. This implies that the duration of metastatic latency is bounded 
below by a certain minimal time τ > 0 during which a metastasis can reach the size N0 if it starts to 
grow from a single cell at a maximum possible rate immediately after seeding. Accordingly, we 
assume that f(t) = 0 for 0 ≤ t ≤ τ and f(t) > 0 for τ < t ≤ W–T. We think of τ as a sufficiently small 
number so that T+τ < V, see Fig. 1. Recall that a typical threshold m corresponds to metastatic 
diameter of about 5 mm while the diameter of metastasis at inception is close to the Folkman’s 
avascular limit of about 1-2 mm. Therefore, m > N0.  
Growth of metastases. To answer our question about the effects that primary tumor and its removal 
exert on the rate of growth of metastases, we have to parameterize one component of our model: the 
laws of growth of metastases before and after primary tumor resection. Quite often, clinical 
metastases are detected early when they are likely to be still in the exponential phase of their growth. 
Therefore, we assume that after inception all viable metastases in the given site grow exponentially 
with two net growth rates, γ0 and γ1, not necessarily distinct, before and after primary tumor 
resection, respectively. Denote by U the inception time of a particular metastasis relative to the age, 
T, of primary tumor inception, see Fig. 1, and let ΨU(t) be the size of the metastasis at time t counted 
from age T+ U. Recall that ΨU(0) = N0. The exponential growth function g(t) = N exp{γt}, t ≥ 0, has 
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the following self-similarity property: g(t) = g(t0)exp{γ(t-t0)}, t ≥ t0, for every t0 > 0. This allows us 
to combine the two exponential growth laws to obtain  
)(tUΨ =



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Effects of surgery. Surgery is assumed to affect metastases only through the rate of their growth 
(and not through a change in the distribution of their latency times). This assumption is plausible 
because dormant tumors are commonly viewed as refractory to various treatments including surgery, 
radiation and chemotherapy [27].  
4. Distribution of the Sizes of Metastases 
Let X be the size of a particular metastasis with inception time U detected in a given site and 
measured at age W. Then according to (1)   
                X = ΨU(W – T – U) = 




≥+−−
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100
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where W–T–U is the total metastasis progression time from inception to detection. An important 
observation is that the function that relates X to the progression time is independent of U:   
                                                             X = Ψ(W – T – U)                                                           (2)                                                                        
where  
                 Ψ(y) = 




−−≤<−−−−
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              (3)                         
Note that function Ψ is increasing, continuous, piecewise differentiable, and satisfies the condition 
Ψ(0) = N0. The inverse function, δ = Ψ -1, is given by  
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where A = N0exp{γ1(W-V)} is the size at age W of a hypothetical metastasis whose inception 
occurred at the time of surgery and M = N0 exp{γ0(V-T-τ)}exp{γ1(W-V)} is the theoretical upper 
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limit for the size of a metastasis measured at age W, i.e. the size of a hypothetical metastasis that 
was shed off the primary tumor at time T and whose inception with size N0 occurred over the shortest 
latency period possible, i.e. at age T+τ, see Fig. 1. Note that N0 < A < M. 
According to formula (2) the sizes of metastases at age W are a fixed non-random transformation Ψ 
of their inception times which, under our model, follow a Poisson process. Then, applying to the 
case at hand a well-known theorem about the conditional joint distribution of the event occurrence 
times in a Poisson process conditional on their number, see e.g. [23, pp. 264–265], we obtain the 
following result.   
Theorem 1. The sizes X1 ≤ X2 ≤ ... ≤ Xn of metastases in a given site that are detectable at age W 
are equidistributed, given their number n, with the vector of order statistics for a random sample of 
size n drawn from the distribution with pdf  
                                 ,
])([)(
](x) T W [)(
  (x)' p(x) }),(min{
0
},(x) - T - min{
0
∫
∫
−−−
−
−−−
−−−
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TVW
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dssfsr
δ
δ
δ
δ
δ    m < x < M ,                (5)              
and p(x) = 0 for x∉(m, M), where δ(x) is given by (4).   
For a proof of Theorem 1 in the case r(t) = αtθ, 0 ≤ t < V-T, with some constants α > 0 and θ ≥ 0, see 
[14]; the proof in the general case is obtained by a minor modification. Distribution (5) depends on 
functional parameters r, f and numerical parameters γ0, γ1. Notice, however, that it is free of 
metastasis survival probability q and sample size n. The patient- and/or site-specific biological 
parameters T, N0, τ, m are assumed fixed.  
In view of (3) we have W–T–δ(x) ≤ V–T if and only if x ≥ Ψ(W–V) = N0 exp{γ1(W–V)} = A. 
Therefore, in the case A ≤ m we have  
                                      ,
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while if A > m then    
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The first and second formulas in (7) account for metastases whose inception occurred after and 
before primary tumor resection, respectively. From (4) we find that δ(M) = W–T–τ. This implies, in 
view of our assumption about the support of pdf f, that p(M-) = 0. Thus, pdf p is continuous at point 
M. By contrast, pdf has jump discontinuity at point m as well as at point A > m, unless γ0 = γ1. That 
is why model (5) does not meet regularity conditions for the consistency of MLEs. Finally, because 
W–T–δ(m) > W–T–δ(M) = τ, the denominator in formulas (6) and (7) is positive.  
Because the Poisson process of metastasis inception is non-stationary, the site-specific sizes of 
metastases at age W do not form a random sample from any probability distribution. However, it 
follows from Theorem 1 that the distribution of any symmetric (i.e. rearrangement-invariant) 
statistic based on the observations X1, X2,..., Xn is identical to the distribution of the same statistic 
based on a random sample of size n drawn from the pdf p given by formula (5). One such symmetric 
statistic is the joint likelihood of observations  
                                                        L(X1, X2,..., Xn) =∏
=
n
k
kXp
1
)(                                                 (8)                          
Thus, pdf p serves, for the purpose of likelihood computation, as a surrogate of the non-existent 
distribution of the “size of a detectable metastasis at age W.” It is also worth mentioning that in the 
case A > m if one of the observations Xk coincides with A then, in order to maximize the likelihood, 
the larger of the two one-sided limits of pdf p at x = A should be employed.  
5. The Main Result 
Because cell cycle duration has a lower limit, the growth rate of any cell population is bounded 
above. Therefore, the net growth rates γ0 and γ1 are bounded above by some constant C. However, 
due to cell death and quiescence they may approach zero. Let G = (0, C) x (0, C) be the set of 
admissible pairs (γ0, γ1). Denote by  
                                                                        
VW
N
X
B
n
−
=
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ln
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the rate of growth of a hypothetical metastasis whose inception occurred at age V and that reached 
size Xn, the largest among the observed sizes of metastases, at age W. The following theorem 
specifies the likelihood-maximizing parameters γ0, γ1. For a detailed proof, see [4].   
Theorem 2. For any fixed functional parameters r, f and for every data set X1, X2,..., Xn   such that 
m < X1 ≤ X2 ≤ ... ≤ Xn , the supremum of the likelihood function L(γ0, γ1) given by (8) over set G is 
infinite. Furthermore, if L(γ0(n), γ1(n)) →  ∞ for some sequence (γ0(n), γ1(n)) in G then γ0(n) 0→  and γ1(n)
B→ .   
Theorem 2 implies that the likelihood-maximizing estimate of parameter vector (γ0, γ1) is (0, B). 
Notice that the estimate γ0 = 0 is independent of the data! By contrast, the estimate γ1 = B is a function 
of the largest observation Xn. Thus, according to the model, the most likely metastasis progression 
scenario for a patient with n metastases detected at age W > V in a given site is as follows: All those 
(say, k) metastases, 1 ≤ k ≤ n, whose inception occurred before resection of the primary tumor 
remained essentially dormant (γ0 →  0) before surgery while after surgery they were growing at a 
rate γ1 close to B and by age W reached sizes close to Xn. Additionally, the remaining n - k metastases 
whose inception occurred after surgery were growing at about the same rate γ1 = B and by age W 
reached more widely spread smaller sizes X1, X2, ..., Xn–k. The model predicts, therefore, that with 
sufficiently high probability the observed data set will contain, along with widely spread sizes of 
metastases whose inception occurred after surgery, some number k ≥ 1 of more tightly clustered 
larger sizes of metastases whose inception occurred prior to surgery. Interestingly, this somewhat 
unexpected pattern was actually observed in all 19 patients the author had analyzed including three 
breast cancer patients [17], twelve prostate cancer patients [18], and four renal cancer patients [21].  
6. Discussion 
Universality of our MLE findings that γ0 = 0 and γ1 > 0 implies that the most likely pathway of 
metastatic cancer progression in an individual patient involves complete suppression of metastatic 
growth while primary tumor is in place followed by its abrupt acceleration following primary tumor 
resection. This scenario is consistent with millions of clinical cases, represents a common knowledge 
among veterinarians, and may be explained by a number of biological mechanisms [4, 11, 12, 28, 
29]. This does not preclude other scenarios; however, they are expected to occur with smaller 
probability. In particular, some metastases may escape the suppressing effects of the primary tumor 
before surgery while others may remain dormant long after surgery. Although the model that has led 
us to these conclusions is extremely general, its modest assumptions are still only an approximation 
to reality. As a result, the qualitative natural law formulated above is expected to only manifest as a 
general trend in a patient- and cancer type-specific manner.  
Derivation of the above clinically significant natural law from a very general mathematical model 
may create an impression of a rabbit extracted from a hat. Such an impression, however, does not 
account for the fact that the model is grounded in three most significant aspects of metastatic cancer 
discovered in the second half of the 20th century. The first is highly selective, multi-stage, stochastic 
nature of metastasis seeding [14, 22]. The second is that dissemination of bloodborne metastases 
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may occur long before primary tumor becomes clinically detectable. This striking finding was 
discovered, initially in the case of breast cancer, through a lifetime of extensive experimental work, 
clinical observations and numerous clinical trials by Bernard Fisher and his colleagues [30, 31]. The 
third is the significance of metastatic dormancy in the form of solitary cancer cells or avascular 
micrometastases [15, 32, 33]. What we have shown mathematically is that under very mild 
assumptions of our model the above natural law holds true for every metastatic progression process 
involving (1) Poisson dissemination interrupted by resection of the primary tumor; (2) random 
independent survival of metastases; (3) their latency with random iid durations; and (4) their 
exponential growth with two fixed rates, one before and one after removal of the primary tumor. 
Thus, the natural law is rooted in very basic temporal and kinetic aspects of metastasis.  
The validity and generality of the discovered natural law depends on how well our model 
assumptions agree with reality. These assumptions fall into two categories: mathematical and 
biomedical. Mathematical premises include, first, homogeneity and independence assumptions, i.e. 
that metastases bound for a given site survive independently of each other with the same probability, 
that their latency times are iid random variables, that they undergo inception in the site with the same 
initial size N0, and that they grow exponentially with the same constant pre- and post-surgery net 
rates γ0 and γ1, respectively. Next, we employed the assumption that metastases are shed according 
to the Poisson process with rate r(t). Due to arbitrariness of the rate function r this essentially reduces 
to stochastic independence of the numbers of metastases shed over non-overlapping time intervals 
and the condition that the probability that multiple metastases were shed over an interval of small 
length h is o(h), see [23, pp. 281-284]. Finally, we postulated certain qualitative properties 
(specifically, continuity and positivity) of functions r and f, see Section 3. All these mathematical 
assumptions are what Henri Poincaré called neutral hypotheses [34]: they facilitate 
conceptualization and mathematical formalization of the phenomenon of interest without unduly 
restricting its scope.  
Biomedical assumptions of our model are minor. One of them, that secondary metastasis is 
negligible, is based on the existing evidence [24]. Although mathematically possible, incorporation 
of secondary metastasis into the model would be impractical, for the generation number of a 
metastasis is largely unobservable. Another assumption posits that resection of primary tumor affects 
metastases through the rate of their growth rather than through a change in their latency times. This 
assumption is based on a well-known fact that quiescent cancer cells and dormant micro-tumors are 
refractory to various environmental signals and therapeutic interventions [27]. Interestingly, in the 
likelihood maximizing limiting case of zero metastatic growth prior to primary tumor excision, the 
phases of metastatic latency and pre-surgery growth become indistinguishable. Biologically, this 
amounts to the extension of metastatic latency until the time of surgery.  
Given that the mechanisms by which primary tumor suppresses metastatic growth remain largely 
hypothetical [11, 28], a question arises as to how bearers of this trait were selected for in the course 
of evolution. In most cases primary tumor is not lethal per se while metastases are. Therefore, any 
spontaneously emerging mechanism of metastasis suppression by primary tumor would confer on 
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the bearers of this trait survival and reproductive advantage over non-bearers while also allowing 
the former to pass it on to their offspring. As a result, the forces of natural selection would fix such 
mechanisms making them dominant across the relevant population.  
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